Patent
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
| العنوان: | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
|---|---|
| Patent Number: | 8,475,794 |
| تاريخ النشر: | July 02, 2013 |
| Appl. No: | 13/209954 |
| Application Filed: | August 15, 2011 |
| مستخلص: | Disclosed herein are compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80, IL-6, CXCR4 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD74 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD74 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD74 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD74 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease, type 1 or type 2 diabetes. |
| Inventors: | Chang, Chien-Hsing (Downingtown, PA, US); Goldenberg, David M. (Mendham, NJ, US); Rossi, Edmund A. (Woodland Park, NJ, US) |
| Assignees: | IBC Pharmaceuticals, Inc. (Morris Plains, NJ, US) |
| Claim: | 1. A method of treating a B cell lymphoma or B cell leukemia comprising a) obtaining a dock-and-lock (DNL) construct that comprises (i) at least one anti-CD74 antibody or antigen-binding fragment thereof that binds to human CD74 and (ii) at least one anti-CD20 antibody or antigen-binding fragment thereof that binds to human CD20, wherein the DNL construct is a hexavalent DNL construct comprising an IgG moiety and four Fab moieties; and b) administering the DNL construct to a human subject with a B-cell lymphoma or B-cell leukemia. |
| Claim: | 2. The method of claim 1 , wherein the anti-CD20 antibody is rituximab or hA20. |
| Claim: | 3. The method of claim 1 , wherein the B-cell lymphoma or B-cell leukemia is selected from the group consisting of mantle cell lymphoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, Burkitt lymphoma, follicular lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia and hairy cell leukemia. |
| Claim: | 4. The method of claim 1 , wherein the anti-CD74 antibody is hLL1. |
| Claim: | 5. The method of claim 1 , wherein the DNL construct is administered by subcutaneous injection. |
| Claim: | 6. The method of claim 1 , wherein the anti-CD74 antibody is a chimeric, humanized or human antibody. |
| Claim: | 7. The method of claim 1 , wherein the anti-CD74 antibody or fragment thereof comprises human IgG1, IgG2, IgG3, or IgG4 constant regions. |
| Current U.S. Class: | 4241/331 |
| Patent References Cited: | 4036945 July 1977 Haber 4046722 September 1977 Rowland 4331647 May 1982 Goldenberg 4699784 October 1987 Shih et al. 4704692 November 1987 Ladner 4816567 March 1989 Cabilly et al. 4824659 April 1989 Hawthorne 4868109 September 1989 Lansdorp et al. 4916213 April 1990 Scannon et al. 4918163 April 1990 Young et al. 4925922 May 1990 Byers et al. 4932412 June 1990 Goldenberg 4946778 August 1990 Ladner et al. 5057313 October 1991 Shih et al. 5106955 April 1992 Endo et al. 5134075 July 1992 Hellstrom et al. 5171665 December 1992 Hellstrom et al. 5196337 March 1993 Ochi et al. 5204095 April 1993 Goodall et al. 5229275 July 1993 Goroff 5443953 August 1995 Hansen et al. 5484892 January 1996 Tedder et al. 5525338 June 1996 Goldenberg 5530101 June 1996 Queen et al. 5565215 October 1996 Gref et al. 5567610 October 1996 Borrebaeck et al. 5593676 January 1997 Bhat et al. 5618920 April 1997 Robinson et al. 5620708 April 1997 Amkraut et al. 5633425 May 1997 Lonberg et al. 5686072 November 1997 Uhr et al. 5693762 December 1997 Queen et al. 5698178 December 1997 Goldenberg 5702727 December 1997 Amkraut et al. 5716595 February 1998 Goldenberg 5734033 March 1998 Reed 5736119 April 1998 Goldenberg et al. 5736137 April 1998 Anderson et al. 5770198 June 1998 Coller et al. 5776456 July 1998 Anderson et al. 5789554 August 1998 Leung et al. 5792845 August 1998 O'Reilly et al. 5795967 August 1998 Aggarwal et al. 5798554 August 1998 Grimaldi et al. 5827690 October 1998 Meade et al. 5874540 February 1999 Hansen et al. 5922302 July 1999 Goldenberg et al. 6051228 April 2000 Aruffo et al. 6051230 April 2000 Thorpe et al. 6077499 June 2000 Griffiths et al. 6096289 August 2000 Goldenberg 6165440 December 2000 Esenaliev 6183744 February 2001 Goldenberg 6187287 February 2001 Leung et al. 6254868 July 2001 Leung et al. 6261537 July 2001 Klaveness et al. 6306393 October 2001 Goldenberg et al. 6331175 December 2001 Goldenberg 6379698 April 2002 Leamon 6387350 May 2002 Goldenberg 6395276 May 2002 Rybak et al. 6524854 February 2003 Monia et al. 6530944 March 2003 West et al. 6562318 May 2003 Filler 6617135 September 2003 Gillies et al. 6653104 November 2003 Goldenberg 6897044 May 2005 Braslawsky et al. 7060506 June 2006 Craig 7074403 July 2006 Goldenberg et al. 7151164 December 2006 Hansen et al. 7312318 December 2007 Hansen et al. 7321026 January 2008 Leung 7338659 March 2008 Leung 7387779 June 2008 Kalluri 7432342 October 2008 Braun et al. 7521056 April 2009 Chang et al. 7527787 May 2009 Chang et al. 7534866 May 2009 Chang et al. 7541440 June 2009 Goldenberg et al. 7550143 June 2009 Goldenberg et al. 7591994 September 2009 Govindan et al. 7666400 February 2010 Chang et al. 7772373 August 2010 Hansen et al. 7829064 November 2010 Griffiths et al. 7858070 December 2010 Chang et al. 7871622 January 2011 Chang et al. 7901680 March 2011 Chang et al. 7906118 March 2011 Chang et al. 7919087 April 2011 Hansen et al. 7931903 April 2011 Hansen et al. 2002/0004587 January 2002 Miller et al. 2002/0009427 January 2002 Wolin et al. 2002/0009444 January 2002 Grillo-Lopez 2002/0018749 February 2002 Hudson et al. 2003/0198956 October 2003 Makowski et al. 2003/0219433 November 2003 Hansen et al. 2003/0232420 December 2003 Braun et al. 2004/0018587 January 2004 Makowski et al. 2004/0076683 April 2004 Hoarau et al. 2005/0003403 January 2005 Rossi et al. 2006/0210475 September 2006 Goldenberg et al. 2007/0020259 January 2007 Hansen et al. 2007/0140966 June 2007 Chang et al. 2009/0060862 March 2009 Chang et al. 2009/0111143 April 2009 Goldenberg et al. 2009/0246214 October 2009 Goldenberg et al. 2010/0015048 January 2010 Hansen et al. 2010/0068137 March 2010 Chang et al. 2010/0104589 April 2010 Govindan et al. 2010/0196266 August 2010 Goldenberg et al. 2010/0266496 October 2010 Hansen et al. 2010/0284906 November 2010 Hansen et al. 2011/0070155 March 2011 Griffiths et al. 2011/0195023 August 2011 Hansen et al. 2011/0244546 October 2011 Hansen et al. 0332865 September 1989 0510949 October 1992 88/04936 July 1988 91/13974 September 1991 92/07466 May 1992 94/11026 May 1994 94/27638 December 1994 9509917 April 1995 96/04925 February 1996 98/42378 October 1998 98/50435 November 1998 99/02567 January 1999 99/54440 October 1999 00/29584 May 2000 0044788 August 2000 00/63403 October 2000 00/67795 November 2000 00/68248 November 2000 00/74718 December 2000 02/056910 July 2002 03/002607 January 2003 WO 03/074567 September 2003 2006/107617 October 2006 2006/107786 October 2006 2007/075270 July 2007 2008/033413 March 2008 |
| Other References: | Stein et al, Clin Cancer Res 10(8): 2868-78, Apr. 2004. cited by examiner Magdelaine-Beuzelin et al, Pharmcogenetics and Genomics 19: 383-387, 2009. cited by examiner Goldenberg et al, blood 113(5): 1062-1070, Jan. 2009. cited by examiner Gupta et al, Blood 116: 3258-3267, 2010. cited by examiner Henry et al, Cancer Res. 64: 7995-8001, Nov. 1, 2004. cited by examiner Riemer et al, Mol. lmmunol. 42: 1121-1124, 2005. cited by examiner Tol et al, N Engl J Med. 360(6):563-72, Feb. 5, 2009. cited by examiner Jubala et al, Vet Pathol 42: 468-476, 2005. cited by examiner Foran et al, Ann Oncol 11(1): 117-121, 2000, Abstract only. cited by examiner Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Comp. 1991, p. 43. cited by applicant Alto et al., “Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring” Proc. Natl. Acad. Sci USA Apr. 15, 2003; 100(8):4445-50. cited by applicant Backer et al., “Self-Assembled “Dock and Lock” System for Linking Payloads to Targeting Proteins” Bioconjugate Chem., 2006, 17(4):912-919. cited by applicant Baillie et al., “Compartmentalisation of phospodiesterases and protein kinase A: opposites attract”, FEBS Letters 2005; 579:3264-3270. cited by applicant Banky et al., “Dimerization/Docking Domain of the Type Iα Regulatory Subunit of cAMP-dependent Protein Kinase”, J. Biol. Chem. 273:35048-55, 1998. cited by applicant Basu et al., “Structure-Function Engineering of Interferon-β-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation”, Bioconjugate Chem. 2006; 17:618-630. cited by applicant Belardelli et al., “Interferon-alpha in tumor immunity and immunotherapy” Cytokine Growth Factor Rev. 13(2):119-134 (2002). cited by applicant Belardelli et al., “International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?” Cancer Res. 64:6827-6830 (2004). cited by applicant Belardelli et al., “The neglected role of type I interferon in the T-cell response: implications for its clinical use” Immunol. Today 17(8):369-72 (1996). cited by applicant Biron et al., “Natural killer cells in antiviral defense: function and regulation by innate cytokines” Annu. Rev. Immunol. 17:189-220 (1999). cited by applicant Brunda et al., “Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons” Cancer Res. 44:597-601 (1984). cited by applicant Burns-Hamuro et al., “Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange” Protein Science (2005), 14:2982-2992. cited by applicant Carr et al., “Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif”, J. Biol. Chem. 266:14188-92 (1991). cited by applicant Carr et al., “Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA” J. Biol. Chem. 276(20):17332-17338 (2001). cited by applicant Carrero et al., “Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes” J. Exp. Med. 203(4):933-940 (2006). cited by applicant Chang et al., “The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity” Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591. cited by applicant Chmura et al., “Antibodies with infinite affinity” Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001). cited by applicant Colledge et al., “AKAPs: from structure to function”, Trends Cell Biol. 6:216-21 (1999). cited by applicant Corbin et al., “Regulation of Adenosine 3′,5′-Monophosphate-dependent Protein Kinase”, J. Biol. Chem. 248:1813-21 (1973). cited by applicant Dhalluin et al., “Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-α2a and Its Individual Positional Isomers” Bioconjugate Chem. 2005;16:504-517. cited by applicant Dodart et al., “Immunotherapy for Alzheimer's Disease: will vaccination work?” Trends Mol. Med. 9(3):85-87 (2003). cited by applicant Doherty et al., “Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor”, Bioconjugate Chem. 2005;16:1291-1298. cited by applicant Ferrantini et al., “IFN-α1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity” J. Immunol. 153:4604-15 (1994). cited by applicant Ferrantini et al., “Interferon-60 and cancer: Mechanisms of action and new perspectives of clinical use” Biochimie 89: 884-893 (2007). cited by applicant Gillies et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes”, J. Immunol. Methods 125 (1989) 191-202. cited by applicant Glennie et al., “Mechanisms of killing by anti-CD20 monoclonal antibodies” Mol. Immunol. 44:3823-3837 (2007). cited by applicant Gold et al., “A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma”, Cancer Res. 68:4819-26, 2008. cited by applicant Gold et al., “Molecular Basis of AKAP Specificity for PKA Regulatory Subunits” Mol. Cell Nov. 3, 2006;24(3):383-95. cited by applicant Goldenberg et al., “Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting”, J. Nucl. Med. 49:158-63, 2008. cited by applicant Goldenberg et al., “Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody” Blood 113:1062-70 (2009). cited by applicant Goodson et al., “Site-Directed PEGylation of Recombinant Interleukin-2 at its Glycosylation Site”, Nat. Biotechnology Apr. 1990;8(4):343-6. cited by applicant Grace et al., “Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-α Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway” J. Biol. Chem. 2005;280(8):6327-6336. cited by applicant Grimley et al., “Prolonged STAT1 Activation Related to the Growth Arrest of Malignant Lymphoma Cells by Interferon-α” Blood 91(8):3017-27 (1998). cited by applicant Gutterman et al., “Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma” Ann. Intern. Med. 93(3):399-406 (1980). cited by applicant Gutterman et al., “Cytokine therapeutics: Lessons from interferon α” Proc. Natl. Acad. Sci. USA 91:1198-205 (1994). cited by applicant Harris et al., “Effect of pegylation on pharmaceuticals” Nat. Rev. Drug. Discov. 2:214-221 (2003). cited by applicant Hausken et al. “Mutational Analysis of the A-Kinase Anchoring Protein (AKAP)-binding Site on RII”, J. Biol. Chem. 271:29016-22 (1996). cited by applicant Hodneland et al., “Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands”, Proc. Natl. Acd. Sci. USA 2002; 99:5048-5052. cited by applicant Huang et al., “Targeting IFN-α to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities” J. Immunol. 179:6881-88 (2007). cited by applicant Hundsrucker et al., “High-affinity AKAP7δ-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides” Biochem. J. (2006) 396, 297-306. cited by applicant Kimby et al., “Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group” Leuk. Lymphoma 49(1):102-112 (2008). cited by applicant Kinderman et al., “A Dynamic Mechanism for AKAP Binding to RII Isoforms of cAMP-Dependent Protein Kinase” Mol. Cell 24(3):397-408 (2006). cited by applicant Kinstler et al., “Characterization and Stability of N-terminally PEGylated rhG-CSF” Pharm. Res. 1996;13 (7):996-1002. cited by applicant Kramer et al., “Cell and virus sensitivity studies with recombinant human alpha interferons” J. Interferon. Res. 3 (4):425-35 (1983). cited by applicant Le Bon et al., “Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo” Immunity 14:461-470 (2001). cited by applicant Lee et al., “Solid-Phase PEGylation of Recombinant Interferon α-2a for Site-Specific Modification: Process Performance, Characterization, and in Vitro Bioactivity” Bioconjugate Chem. 2007; 18:1728-34. cited by applicant Lohmann et al., “High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins”, Proc. Natl. Acad. Sci. USA 81:6723-27 (1984). cited by applicant Luft et al., “Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells” J. Immunol. 161:1947-1953 (1998). cited by applicant Mason, Anthony J., “Functional Analysis of the Cysteine Residues of Activin A”, Mol. Endocrinol. 8:325-32, 1994. cited by applicant Matarrese et al., “Type I Interferon Gene Transfer Sensitizes Melanoma Cells to Apoptosis via a Target Activity on Mitochondrial Function” Am. J. Pathol. 2002, 160(4):1507-1520. cited by applicant Mecchia et al., “Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha”, Gene Ther. (2000) 7, 167-179. cited by applicant Newlon et al., “A Novel Mechanism of PKA Anchoring Revealed by Solution Structures of Anchoring Complexes”, Embo J. 2001; 20:1651-1662. cited by applicant Newlon et al., “The molecular basis for protein kinase A anchoring revealed by solution NMR”, Nature Stud. Biol. 1999; 3:222-227. cited by applicant Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, Ch. 14, pp. 492-495, (Mertz & Le Grand, Eds.), Birkhauser Boston, 1994. cited by applicant Osborn et al., “Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys”, J. Pharmacol. Exp. Ther. 303(2):540-548 (2002). cited by applicant Oyen et al., “Human testis cDNA for the regulatory subunit Rllα of cAMP-dependent protein kinase encodes an alternate amino-terminal region”, FEBS Letters 246:57-64, 1989. cited by applicant Ozzello et al., “Conjugation of interferon alpha to a humanized monoclonal antibody (HuBrE-3vl) enhances the selective localization and antitumor effects of interferon in breast cancer xenografts”, Breast Cancer Res. Treat. 48: 135-147 (1998). cited by applicant Paquette et al., “Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells”, J. Leukoc. Biol. 64:358-367; 1998. cited by applicant Pelham et al., “Interferon-α conjugation to human osteogenic sarcoma monoclonal antibody 791T/36”, Cancer Immunol. Immunother. 1983;15(3):210-216. cited by applicant Pepinsky et al., “Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-β-1a with Preserved in Vitro Bioactivity”, Pharmacol. Exp. Ther. 2001; 297(3):1059-1066. cited by applicant Pilling et al., “Interferon-β mediates stromal cell rescue of T cells from apoptosis”, Eur. J. Immunol. 29:1041-1050 (1999). cited by applicant Rabjohn et al., “Molecular Cloning and Epitope Analysis of the Peanut Allergen Ara h 3”, J. Clinical Investigation 103 (4):535-542 (1999). cited by applicant Raefsky et al., “Studies of Interferon as a regulator of hematopoietic cells proliferation”, J. Immunol. 135 (4):2507-2512 (1985). cited by applicant Rose et al., “Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1α”, Nature Struct. Biol. 2000; 7:744-748. cited by applicant Rosendahl et al., “A Long-Acting, Highly Potent Interferon α-2 Conjugate Created Using Site-Specific PEGylation”, Bioconjugate Chem. 2005;16:200-207. cited by applicant Rossi et al., “Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics”, Cancer Res. 68:8384-92, 2008. cited by applicant Rossi et al., “Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting” Proc. Natl. Acad. Sci. Epub Apr. 24, 2006, vol. 103, No. 18, pp. 6841-6846. cited by applicant Rustandi et al., “The Ca2+-Dependent Interaction of S100B(ββ) with a Peptide Derived from p53”, Biochemistry 1998; 37: 1951-1960. cited by applicant Sabaawy et al., “Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-β gene transfer”, Int. J. Oncol. Jun. 1999; 14(6):1143-51. cited by applicant Salles et al., “Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study”, Blood 2008; 112:4824-4831. cited by applicant Santini et al., “Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity In Vivo and in Hu-PBL-SCID Mice”, J. Exp. Med. 191(10):1777-1788 (2000). cited by applicant Scott et al., “Type II Regulatory Subunit Dimerization Determines the Subcellular Localization of the cAMP-dependent Protein Kinase”, J. Biol. Chem. 265:21561-66 (1990). cited by applicant Scott et al., “Cyclic nucleotide-dependent protein kinases”, Pharmacol. Ther. 1991;50(1):123-45. cited by applicant Seffernick et al., “Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different”, J. Bacteriol. 183(8):2405-2410 (2001). cited by applicant Sharkey et al., “Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody”, Cancer Res. 68:5282-90, 2008. cited by applicant Sharkey et al., “Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model”, Radiology 246:497-507, 2008. cited by applicant Sidky et al., “Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses”, Cancer Res. 47:5155-5161, Oct. 1, 1987. cited by applicant Stein et al., “Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma”, Clin. Cancer Res. vol. 10, 2868-2878, Apr. 15, 2004. cited by applicant Stein et al., “Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab”, Blood 2006;108:2736-2744. cited by applicant Stokka et al., “Characterization of A-kinase-anchoring disruption using a solution-based assay”, Biochem. J. (2006) 400, 493-499. cited by applicant Stryer et al., “Levels of Structure in Protein Architecture”, Biochemistry, 3rd Ed., pp. 31-33, W.H. Freeman & Co., New York, 1988. cited by applicant Takaoka et al., “Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence”, Nature Jul. 31, 2003;424(6948):516-23. cited by applicant Taylor, S., “cAMP-dependent Protein Kinase”, J. Biol. Chem. 1989;264(15):8443-8446. cited by applicant Walsh et al., “An Adenosine 3′, 5′-Monophosphate-dependant Protein Kinase from Rabbit Skeletal Muscle”, J. Biol. Chem. 243(13):3763-3774 (1968). cited by applicant Weck et al., “Comparison of the Antiviral Activities of Various Cloned Human Interferon-α Subtypes in Mammalian Cell Cultures”, J. Gen. Virol. (1981), 57, 233-237. cited by applicant Winkler et al., “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody”, J. Immunol. 165:4505-14, 2000. cited by applicant Witkowski et al., “Conversion of a β-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine”, Biochemistry 38(36):11643-50 (1999). cited by applicant Wong et al., “AKAP Signalling Complexes: Focal Points in Space and Time”, Nat. Rev. Mol. Cell Biol. 12:959-70 (2004). cited by applicant Zhu et al., “Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor”, Invest. New Drugs 17:195-212, 1999. cited by applicant Patti et al., “High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas”, Eur J Haematol. Jul. 1993;51(1):18-24. cited by applicant Press et al., “Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas”, Blood. Feb. 1987;69 (2):584-91. cited by applicant Press et al., “Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody”, J Clin Oncol. Aug. 1989;7(8):1027-38. cited by applicant Press et al., “Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates”, Cancer J. Sci. Am. 4(Suppl 2):S19-26 (1998). cited by applicant Price, K. M., “Production and characterization of synthetic peptide-derived antibodies”, Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al., (Eds.), pp. 60-84, Cambridge University Press (1995). cited by applicant Protheroe et al., “Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma”, Rheumatology (Oxford) 38(11):1150-2 (1999). cited by applicant Qu et al., “Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates”, J. Immunol. Methods 213(2):131-44 (1998). cited by applicant Qu et al., “Internalization and cytotoxic effects of a humanized anti-CD74 antibody, LL1”, Proc Am Assoc Cancer Res 2002;43:255, Abstract #1269. cited by applicant Raag et al., “Single-chain Fvs”, FASEB J. 9(1):73-80 (1995). cited by applicant Renner et al., “Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects”, Leukemia 11(Suppl 2):S55-9 (1997). cited by applicant Riechmann et al., “Reshaping human antibodies for therapy”, Nature 332(6162):323-7 (1988). cited by applicant Robinson et al., “Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities”, Hum Antibodies Hybridomas. Apr. 1991;2(2):84-93. cited by applicant Rowan et al., “Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells”, Immunology 95(3):427-36 (1998). cited by applicant Rudikoff et al., ''Single amino acid substitution altering antigen-binding specificity', Proc. Natl. Acad. Sci. USA 79 (6):1979-83 (1982). cited by applicant Ryser et al., “Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells”, Proc. Natl. Acad. Sci. USA 75(8):3867-70 (1978). cited by applicant Saltzman et al., “Transport rates of proteins in porous materials with known microgeometry”, Biophys. J. 55 (1):163-71 (1989). cited by applicant Sambrook et al., “Molecular Cloning”, a Laboratory Manual, 2nd Edition, 1989, Cold Spring harbor Laboratory Press, USA. cited by applicant Sandhu, J. S., “Protein engineering of antibodies”, Crit. Rev. Biotechnol. 12(5-6):437-62 (1992). cited by applicant Sanger et al., “DNA sequencing with chain-terminating inhibitors”, Proc Natl Acad Sci U S A. Dec. 1977;74 (12):5463-7. cited by applicant Schlom, J. “Monoclonal Antibodies: They're More and Less Than You Think”, Molecular Foundations of Oncology, Broader, S. (Ed.), pp. 95-134 (1991). cited by applicant Shan et al., “Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells”, Cancer Immunol Immunother. Mar. 2000;48(12):673-83. cited by applicant Sherwood et al., “Controlled antibody delivery systems”, Biotechnology 10(11):1446-9 (1992). cited by applicant Shih et al., “Site-specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier”, Int J Cancer 41(6):832-9 (1988). cited by applicant Shih et al., “A fluorouridine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model”, Int. J. Cancer 46(6):1101-6 (1990). cited by applicant Shih et al., “Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2”, Int J Cancer 56(4):538-45 (1994). cited by applicant Shih et al., “Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice”, Cancer Immunol. Immunother. 49(4-5):208-16 (2000). cited by applicant Shopes, B., “A genetically engineered human IgG mutant with enhanced cytolytic activity”, J Immunol. May 1, 1992;148(9):2918-22. cited by applicant Singer et al., “Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences”, J. Immunol. 150(7):2844-57 (1993). cited by applicant Stein et al., “Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2”, Cancer Immunol. Immunother. 37(5):293-8 (1993). cited by applicant Straubinger et al., “Endocytosis and intracellular fate of liposomes using pyranine as a probe”, Biochemistry 29 (20):4929-39 (1990). cited by applicant Tatsuta et al., “Diagnosis of gastric cancers with fluorescein-labeled monoclonal antibodies to carcinoembryonic antigen”, Lasers Surg. Med. 9(4):422-6 (1989). cited by applicant Taylor et al., “A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins”, Nucleic Acids Res. 20(23):6287-95 (1992). cited by applicant Taylor et al., “Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM”, Int Immunol. Apr. 1994;6(4):579-91. cited by applicant Tempest et al., “Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo”, Biotechnology 9(3):266-71 (1991). cited by applicant Theocharis et al., “Characterization of in vivo mutated T cell clones from patients with systemic lupus erythematosus”, Clin. Immunol. Immunopathol. 74(2):135-42 (1995). cited by applicant Thorpe et al., “Monoclonal antibodies: clinical and regulatory issues”, Trends Biotechnol. 11(2):40-2 (1993). cited by applicant Torchilin et al., “The antibody-linked chelating polymers for nuclear therapy and diagnostics”, Crit. Rev. Ther. Drug Carrier Syst. 7(4):275-308 (1991). cited by applicant Torchilin et al., “Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs”, Proc. Natl. Acad. Sci. USA 100(10):6039-44 (2003). cited by applicant Upeslacis et al., “Modification of Antibodies by Chemical Methods,” Monoclonal Antibodies: Principles and Applications, Birch et al. (eds.), pp. 187-230 (Wiley-Liss, Inc., 1995). cited by applicant Van Den Bergh, H., “Light and porphyrins in cancer therapy”, Chem. Britain 22:430 (1986). cited by applicant Vaughan et al., “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library”, Nat. Biotechnol. 14(3):309-14 (1996). cited by applicant Verhoeyen et al., “Reshaping human antibodies: grafting an antilysozyme activity”, Science 239(4847):1534-6 (1988). cited by applicant Vuist et al., “Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model”, Cancer Res. 49(14):3783-8 (1989). cited by applicant Ward et al., “Genetic Manipulation and Expression of Antibodies,” Monoclonal Antibodies: Principles and Applications, Birch et al., (eds.), pp. 137-185 (Wiley-Liss, Inc. 1995). cited by applicant Werner et al., “Appropriate mammalian expression systems for biopharmaceuticals”, Arzneimittelforschung. Aug. 1998;48(8):870-80. cited by applicant West et al., “Applications of nanotechnology to biotechnology commentary”, Curr Opin Biotechnol. 11(2):215-7 (2000). cited by applicant Wong, S. Chemistry of Protein Conjugation and Cross-Linking, CRC Press, Inc. (1991). cited by applicant Wrobel et al., “Fusion of cationic liposomes with mammalian cells occurs after endocytosis”, Biochim. Biophys. Acta. 1235(2):296-304 (1995). cited by applicant Xu et al., “Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes”, Mol. Cancer Ther. 1(5):337-46 (2002). cited by applicant Yu et al., “Peptide-antibody conjugates for tumour therapy: a MHC-class-II-restricted tetanus toxin peptide coupled to an anti-Ig light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells”, Int. J. Cancer 56(2):244-8 (1994). cited by applicant US 6,558,648, May 2003, Griffiths et al., (withdrawn). cited by applicant Bagshawe et al., “Developments with targeted enzymes in cancer therapy”, Curr. Opin. Immunol. 11(5):579-83 (1999). cited by applicant Bally et al. (Eds.), “Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations”, Journal of Liposome Research, 1998, vol. 8, No. 3, pp. 299-335. cited by applicant Beers et al., The Merck Manual of Diagnosis and Therapy, Ch. 180, p. 1474-1476; 17th Ed., Whitehouse Station, NJ, Merck Research Labs (1999). cited by applicant Bendas et al., “Immunoliposomes: a promising approach to targeting cancer therapy”, BioDrugs 15(4):215-24 (2001). cited by applicant Bendig, M., “Humanization of Rodent Monoclonal Antibodies by CDR Grafting”, Academic Press Inc., New York, NY, vol. 8, (1995), pp. 83-93. cited by applicant Bird et al., “Single chain antibody variable regions”, Trends Biotechnol. 9(4):132-7 (1991). cited by applicant Bom et al., “The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity”, J. Control Release 74(1-3):325-33 (2001). cited by applicant Breen et al., “Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype”, Clin. Immunol. 109(2):119-29 (2003). cited by applicant Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue”, J. Cell Biol. 111:2129-2138 (1990). cited by applicant Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy”, Proc. Natl. Acad. Sci. USA 89(10):4285-9 (1992). cited by applicant Chen et al., “Differential Effects of Milatuzumab on Human Antigen-Presenting Cells in Comparison to Malignant B Cells”, 2009 ASH Annual Meeting Abstracts, vol. 114(22)1073; Abstr #2744 (Nov. 20, 2009). cited by applicant Cochlovius et al., “Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation”, Cancer Res. 60(16):4336-41 (2000). cited by applicant Coligan et al., (Eds.), Current Protocols in Immunology, vol. 1, pp. 2.5.1-2.6.7; pp. 2.7.1.-2.7.12; pp. 2.8.1-2.8.10; pp. 2.9.1-2.9.3; pp. 2.10.-2.10.4; John Wiley & Sons, Inc., 1991. cited by applicant Colman, P., “Effects of amino acid sequence changes on antibody-antigen interactions”, Res. Immunol. 1994, 145:33-36. cited by applicant Coloma et al., “Design and production of novel tetravalent bispecific antibodies”, Nat. Biotechnol. 15(2):159-63 (1997). cited by applicant Constantinides et al., “Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel”, Pharm. Res. 17(2):175-82 (2000). cited by applicant Courtenay-Luck, N. S., “Genetic manipulation of monoclonal antibodies”, Monoclonal Antibodies: Production, Engineering and Clinical Application, p. 166-179, Ritter et al. (Eds.), Cambridge University Press (1995). cited by applicant Fitzgerald et al., “Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris”, Protein Eng. 10(10):1221-5 (1997). cited by applicant Flavell et al., “Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice”, Cancer Res. 57:4824-9 (1997). cited by applicant Freedman et al., “Non-Hodgkin's Lymphomas”, Cancer Medicine, 3rd Ed., vol. 2, p. 2028-2068, Holland et al., (Eds.), Lea & Febiger (1993). cited by applicant French et al., “Response of B-cell lymphoma to a combination of bispecific antibodies and saporin”, Leuk. Res. 20 (7):607-17 (1996). cited by applicant Ghetie et al., “Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy”, Cancer Res. 48(9):2610-7 (1988). cited by applicant Ghetie et al., “Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin”, Blood. Mar. 1, 2001;97(5):1392-8. cited by applicant Gold et al., “Expression of CD74 in pancreatic and colorectal carcinomas as a basis for milatuzumab immunotherapy”, Abstract #5485; Proceeding of the American Association for Cancer Research, vol. 50, p. 1322-1323; Apr. 2009. cited by applicant Goldenberg, D. M. “Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy”, Semin. Nucl. Med. 19(4):332-9 (1989). cited by applicant Goldenberg et al., “Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody”, J Clin Oncol. Apr. 1991;9(4):548-64. cited by applicant Goldenberg, D. M. “Radiolabeled antibodies”, Science & Medicine, 1(1):64 (Apr. 1994). cited by applicant Goldenberg, D. M. “New Developments in Monoclonal Antibodies for Cancer Detection and Therapy”, CA Cancer J. Clin. 44(1):43-64 (1994). cited by applicant Gondo et al., “HLA class II antigen associated invariant chain gene expression in malignant lymphoma”, Br. J. Haematol. 67(4):413-7 (1987). cited by applicant Goto et al. “A novel membrane antigen selectively expressed on terminally differentiated human B cells”, Blood 84 (6):1922-30 (1994). cited by applicant Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs”, Nature Genetics 7:13-21 (1994). cited by applicant Greenwood et al., “Effector functions of matched sets of recombinant human IgG subclass antibodies”, Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Clark (Ed.), p. 89; p. 97; Academic Titles (1993). cited by applicant Griffiths et al., “Cure of SCID Mice Bearing Human B-Lymphoma Xenografts by an Anti-CD74 Antibody-Anthracycline Drug Conjugate”, vol. 9, 6567-6571, Dec. 15, 2003. cited by applicant Hansen et al., “Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas”, Biochem. J. 1996, 320:293-300. cited by applicant Hasan et al., “Laser-induced selective cytotoxicity using monoclonal antibody-chromophore conjugates”, Prog. Clin. Biol. Res. 288:471-7 (1989). cited by applicant Hekman et al. “Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody”, Cancer Immunol. Immunother. 1991;32(6):364-72. cited by applicant Hess et al., “Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide”, Blood 89(6):2203-9 (1997). cited by applicant Hong et al., “pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system”, J. Pharm. Pharmacol. 54(1):51-8 (2002). cited by applicant Hua et al., “Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung”, Hum. Pathol. 29(12):1441-6 (1998). cited by applicant Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”, Science 246:1275-1281 (1989). cited by applicant Ibragimova et al., “Stability of the beta-sheet of the WW domain: A molecular dynamics simulation study”, Biophys. J. 77(4):2191-8 (1999). cited by applicant Johnson et al., “Human antibody engineering”, Current Opin. Struct. Biol. 3:564-571 (1993). cited by applicant Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse” Nature 321(6069):522-5 (1986). cited by applicant Juweid et al., “99Tcm-LL1: a potential new bone marrow imaging agent”, Nucl. Med. Commun. 18(2):142-8 (1997). cited by applicant Juweid et al., “Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody”, Cancer Res. 55(23 Suppl):5899s-5907s (1995). cited by applicant Kaminski et al., “Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody”, N. Engl. J. Med. 329(7):459-65 (1993). cited by applicant Kiesel et al., “Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis”, Leuk. Res. 11(12):1119-25 (1987). cited by applicant Kirpotin et al., “Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro”, Biochemistry 36(1):66-75 (1997). cited by applicant Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature 256:495-7 (1975). cited by applicant Kolata, G., “Clinical promise with new hormones”, Science 236:517-519 (1987). cited by applicant Koning et al., “Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells”, Biochim. Biophys. Acta. 1420(1-2):153-67 (1999). cited by applicant Kratz et al., “Drug-polymer conjugates containing acid-cleavable bonds”, Crit. Rev. Ther. Drug Carrier Syst. 16 (3):245-88 (1999). cited by applicant Kreitman et al., “Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice”, Cancer Res. 53(4):819-25 (1993). cited by applicant Larrick et al., “PCR Amplification of Antibody Genes”, Methods: A Companion to methods in Enzymology 2 (2):106-110 (1991). cited by applicant Lazar et al.,“Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities”, Mol. Cell. Biol. 8(3):1247-1252 (1988). cited by applicant Leonard et al., “Epratuzumab, a new Anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): phase I/II trial results”, Blood 94:92a-93a, Abstract # 404, (1999). cited by applicant Leung et al., “Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell Lymphoma”, Hybridoma 13 (6):469-476 (1994). cited by applicant Leung et al., “Engineering a Unique Glycosylation Site for Site-Specific Conjugation of Haptens to Antibody Fragments”, J. Immunol. 154:5919-5926 (1995). cited by applicant Leung et al., “Construction and characterization of a humanized, internalizing, b-cell (CD22)-specific, leukemia/lymphma antibody, LL2”, Mol. Immunol. 32(17/18):1413-1427 (1995). cited by applicant Levine et al., “IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab”, Neurology 52 (8):1701-4 (1999). cited by applicant Li et al., “The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies”, Cell Immunol. 118(1):85-99 (1989). cited by applicant Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications”, Nature 368:856-9 (1994). cited by applicant Longo, D. L., “Immunotherapy for non-Hodgkin's lymphoma”, Curr. Opin. Oncol. 8(5):353-9 (1996). cited by applicant Lopez De Menezes et al., “In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma”, Cancer Res. 58(15):3320-30 (1998). cited by applicant Lopez De Menezes et al., “Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells”, J. Liposome Research 1999, vol. 9, No. 2 , pp. 199-228. cited by applicant Lundberg, B., “Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures”, J. Pharm. Sci. 83(1):72-5 (1994). cited by applicant Lundberg, B., “The solubilization of lipophilic derivatives of podophyllotoxins in sub-micron sized lipid emulsions and their cytotoxic activity against cancer cells in culture”, Int. J. Pharm. 109:73-81 (1994). cited by applicant Lundberg et al., “Submicron lipid emulsions containing amphipathic polyethylene glycol for use as drug-carriers with prolonged circulation time”, Int. J. Pharm. 134:119-127 (1996). cited by applicant Lundberg et al., A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol), J Pharm Pharmacol. 49:16-21 (1997). cited by applicant Lundberg et al., “Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions”, Anticancer Drug Des. 13(5):453-61 (1998). cited by applicant Lundberg et al., “Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions”, J. Pharm. Pharmacol. 51(10):1099-105 (1999). cited by applicant Lundberg et al., “Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin”, Int. J. Pharm. 205(1-2):101-8 (2000). cited by applicant Lundberg et al., “Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells”, J. Control. Release 94(1):155-61 (2004). cited by applicant Mack et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity”, Proc. Natl. Acad. Sci. USA 92:7021-7025 (1995). cited by applicant Maloney et al., “Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma”, Blood 84(8):2457-66 (1994). cited by applicant Maranhao et al., “Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients”, Cancer Chemother. Pharmacol. 49(6):487-98 (2002). cited by applicant McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains”, Nature 348:552-553 (1990). cited by applicant Mendez et al., “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice”, Nature Genetics 15:146-156 (1997). cited by applicant Mew et al., “Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates”, J. Immunol. 130(3):1473-7 (1983). cited by applicant Mew et al., “Ability of Specific Monoclonal Antibodies and Conventional Antisera Conjugated to Hematoporphyrin to Label and Kill Selected Cell Lines Subsequent to Light Activation”, Cancer Res. 45:4380-4386 (1985). cited by applicant Moase et al., “Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer”, Biochim. Biophys. Acta. 1510(1-2):43-55 (2001). cited by applicant Moller et al., “CD74”, J. Biol. Regul. Homeost. Agents 14(4):299-301 (2000). cited by applicant Mosmann, T., “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays”, J. Immunol. Methods 65(1-2):55-63 (1983). cited by applicant Nagel et al., “HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3”, Leukemia 19(5):841-6 (2005). cited by applicant Nakagawa et al., “Clinical trial of intrathecal administration of 5-fluoro-2′-deoxyuridine for treatment of meningeal dissemination of malignant tumors”, J. Neurooncol. 45(2):175-83 (1999). cited by applicant Nisonoff et al., “Separation of Univalent Fragments from the Bivalent Rabbit Antibody Molecule by Reduction of Disulfide Bonds”, Arch. Biochem. Biophys. 89:230-244 (1960). cited by applicant Ochakovskaya et al., Therapy of Disseminated B-Cell Lymphoma Xenografts in Severe Combined Immunodeficient Mice with an Anti-CD74 Antibody Conjugated with (111)Indium, (67)Gallium, or (90)Yttrium, Clin. Cancer Res. 7(6):1505-1510 (2001). cited by applicant Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction”, Proc. Natl. Acad. Sci. USA 86:3833-3837 (1989). cited by applicant Oseroff et al., “Antibody-targeted photolysis: Selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates”, Proc. Natl. Acad. Sci. USA 83:8744-8748 (1986). cited by applicant Oseroff et al., “Strategies for selective cancer photochemotherapy: antibody-targeted and selective carcinoma cell photolysis”, Photochem. Potobiol. 46(1):83-96 (1987). cited by applicant Oster et al., “Erythropoietin for the Treatment of Anemia of Malignancy Associated with Neoplastic Bone Marrow Infiltration”, J. Clin. Oncol. 8(6):956-962 (1990). cited by applicant Pastan et al., “Immunotoxins”, Cell 47:641-648 (1986). cited by applicant Patti et al., “High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas”, Eur. J. Haematol. 51(1):18-24 (1993). cited by applicant Pawlak-Byczkowska et al., “Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma”, Cancer Res. 49(16):4568-77 (1989). cited by applicant Pelegrin et al., “Antibody-Fluorescein Conjugates for Photoimmunodiagnosis of Human Colon Carcinoma in Nude Mice”, Cancer 67:2529-2537 (1991). cited by applicant Perkins et al., “Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds”, Int. J. Pharm. 200(1):27-39 (2000). cited by applicant Pirker et al., “Characterization of immunotoxins active against ovarian cancer cell lines”, J. Clin. Invest. 76(3):1261-7 (1985). cited by applicant Porter et al., “The Hydrolysis of Rabbit γ-Globulin and Antibodies with Crystalline Papain”, Biochem. J. 73 (1):119-127 (1959). cited by applicant Press et al., “Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support”, N. Engl. J. Med. 329(17):1219-24 (1993). cited by applicant Press et al., “Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas”, Lancet 346:336-40 (1995). cited by applicant Alinari et al., “FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death”, Blood. Oct. 31, 2011. [Epub ahead of print]. cited by applicant Ansel et al. (Eds.), “Pharmaceutical Dosage Forms and Drug Delivery Systems”, 5th Edition, Lippincott Williams & Wilkins, 1990. cited by applicant Appelbaum, F., “Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma”, Hematol. Oncol. Clin. North Am. Oct. 1991;5(5):1013-25. cited by applicant Ausubel et al. (Eds.), “Current Protocols in Molecular Biology”, vol. 1, Unit 8, John Wiley & Sons, Inc., 1994. cited by applicant Baines et al., “Purification of Immunoglobulin G (IgG)”, Methods in Molecular Biology, 1992, vol. 10, p. 79-104. cited by applicant Barnes et al., “Advances in animal cell recombinant protein production: GS-NS0 expression system”, Cytotechnology Feb. 2000:32(2):109-23. cited by applicant Berkova et al., “Milatuzumab—a promising new immunotherapeutic agent”, Expert Opin Investig Drugs. Jan. 2010;19 (1):141-9. cited by applicant Binsky et al., “IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival”, Proc Natl Acad Sci U S A. Aug. 14, 2007;104(33):13408-13. cited by applicant Binsky et al., “TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner”, J Immunol. May 1, 2010;184(9):4761-9. cited by applicant Burton et al., “CD74 is expressed by multiple myeloma and is a promising target for therapy”, Clin Cancer Res. Oct. 1, 2004;10(19):6606-11. cited by applicant Caron et al., “Engineered humanized dimeric forms of IgG are more effective antibodies”, J. Exp. Med. Oct. 1, 1992;176(4):1191-5. cited by applicant Chang et al., “Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin”, Blood. Dec. 15, 2005;106(13):4308-14. cited by applicant Colman et al., “Production of therapeutic proteins in the milk of transgenic livestock”, Biochem. Soc. Symp. 1998;63:141-7. cited by applicant Devesa et al., “Cancer incidence and mortality trends among whites in the United States, 1947-84”, J. Natl. Cancer Inst. Oct. 1987;79(4):701-70. cited by applicant Eary et al., “Imaging and treatment of B-cell lymphoma”, J. Nucl. Med. Aug. 1990;31(8):1257-68. cited by applicant Eisenberg et al., “The therapeutic potential of anti-CD20 what do B-cells do?”, Clin. Immunol. Dec. 2005;117 (3):207-13. cited by applicant Foon et al., “Chronic lymphocytic leukemia: new insights into biology and therapy”, Ann. Intern. Med. Oct. 1, 1990;113 (7):525-39. cited by applicant Freedman, A., “Immunobiology of chronic lymphocytic leukemia”, Hematol. Oncol. Clin. North Am. Apr. 1990;4 (2):405-29. cited by applicant Gennaro, A.R., Remington: 19th Edition, 1995, Mack Publishing Co. cited by applicant Ghetie et al., “Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells”, Proc. Natl. Acad. Sci. USA Jul. 8, 1997;94(14):7509-14. cited by applicant Gilles et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes”, J. Immunol. Methods Dec. 20, 1989;125(1-2):191-202. cited by applicant Gold et al., “Enhanced expression of CD74 in gastrointestinal cancers and benign tissues”, Int J Clin Exp Pathol. Nov. 23, 2010;4(1):1-12. cited by applicant Goldenberg et al., “Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells In Vivo”, Int J Cancer. Jul. 27, 2011. cited by applicant Goodman et al., The Pharmacological Basis of Therapeutics, 5th Edition, 1975, MacMillan Publishing Co., Inc., USA. cited by applicant Goodman et al., “New perspectives on the approach to chronic lymphocytic leukemia”, Leuk. Lymphoma Jun. 1996;22(1-2):1-10. cited by applicant Gopal et al., “Clinical applications of anti-CD20 antibodies”, J. Lab. Clin. Med. Nov. 1999;134(5):445-50. cited by applicant Gorman et al., “B cell depletion in autoimmune disease”, Arthritis Res. Ther. 2003;5 Suppl 4:S17-21. cited by applicant Govindan et al., “Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters”, J Nucl Med. Dec. 2000;41(12):2089-97. cited by applicant Griffiths et al., “Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies”, Int J Cancer. Jun. 11, 1999;81(6):985-92. cited by applicant Hertlein et al., “Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells”, Blood. Oct. 7, 2010;116(14):2554-2558. cited by applicant Jori et al., (Eds.), Photodynamic Therapy of Tumours and Other Diseases, Libreria Progetto (1985). cited by applicant Kazkaz et al., “Anti B cell therapy (rituximab) in the treatment of autoimmune diseases”, Curr. Opin. Pharmacol. Aug. 2004;4(4):398-402. cited by applicant Liu et al., “Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity”, J. Immunol. Nov. 15, 1987;139(10):3521-6. cited by applicant Losman et al., “Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2)”, Cancer Dec. 15, 1997;80(12 Suppl):2660-6. cited by applicant Maloney et al., “Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies”, Oncology (Williston Park) Oct. 1998;12(10 Suppl 8):63-76. cited by applicant Mark et al., “Milatuzumab: a promising new agent for the treatment of lymphoid malignancies”, Expert Opin Investig Drugs. Jan. 2009;18(1):99-104. cited by applicant Michel et al., “Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons”, Clin Cancer Res. Jan. 15, 2005;11(2 Pt 1):777-86. cited by applicant Michel et al., “177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo”, Nucl Med Biol. Apr. 2005;32(3):269-78. cited by applicant Ong et al., “Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines”, Immunology. Oct. 1999;98(2):296-302. cited by applicant Ong et al., “Single-cell cytotoxicity with radiolabeled antibodies”, Clin Cancer Res. Jan. 2001;7(1):192-201. cited by applicant Paul, W., Fundamental Immunology, 3rd Edition, pp. 292-295 (1993). cited by applicant Sapra et al., “Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys”, Clin Cancer Res. Jul. 15, 2005;11(14):5257-64. cited by applicant Shachar et al., The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival, Leuk Lymphoma. Aug. 2011;52(8):1446-54. cited by applicant Shan et al., “Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths”, J. Immunol. Jun. 1, 1999;162(11):6589-95. cited by applicant Sharkey et al., Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma, J Nucl Med. Mar. 2009;50(3):444-53. cited by applicant Stein et al., “Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies”, Blood. Dec. 1, 2004;104(12):3705-11. cited by applicant Stein et al., “CD74: a new candidate target for the immunotherapy of B-cell neoplasms”, Clin Cancer Res. Sep. 15, 2007;13(18 Pt 2):5556s-5563s. cited by applicant Stein et al., “Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines”, Clin Cancer Res. Apr. 15, 2009;15(8):2808-17. cited by applicant Stein et al., “Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways”, Blood. Jun. 24, 2010;115 (25):5180-90. cited by applicant Tesch et al., “Treatment of patients with malignant lymphomas with monoclonal antibodies”, Bone Marrow Transplant May 2000;25 Suppl 2:S50-3. cited by applicant Jefferis et al., “Human immunoglobulin allotypes: possible implications for immunogenicity”, MAbs 1(4):1-7 (2009). cited by applicant |
| Primary Examiner: | Huynh, Phuong |
| Attorney, Agent or Firm: | Nakashima, Richard A. |
| رقم الانضمام: | edspgr.08475794 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |